Kairos Pharma signs term sheet to acquire CL-741, a Phase 1-ready c-MET inhibitor; outlines 2026 milestones

Kairos Pharma, LTD.

• Acquiring worldwide rights to CL-741, an oral type IIb c-MET kinase inhibitor targeting EGFR-mutated lung cancer and esophageal/gastric cancers.
• CL-741 is Phase 1-ready; Phase 1 study initiation planned for H2 2026.
• ENV-105 Phase 2 trial in prostate cancer continues; more trial sites expected by year-end.
• ENV-105 Phase 1 in NSCLC results anticipated by Q3 2026.
• Over $8M in non-dilutive funding; low monthly burn rate highlighted.